Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | ARNT | P27540 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13590954 | 0.81 | IDO1 (0.54) | IDO1EPHX2P2RX7HDAC3HDAC1 | |
| SCHEMBL6077476 | 0.79 | IDO1 (0.48) | IDO1P2RX7 | |
| SCHEMBL16972742 | 0.77 | HDAC3 (0.55) | IDO1EPHX2P2RX7HDAC3HDAC1 | |
| SCHEMBL19534981 | 0.77 | IDO1 (0.69) | IDO1EPHX2P2RX7HDAC3HDAC1 | |
| SCHEMBL31488381 | 0.77 | P2RX7 (0.41) | IDO1P2RX7SLC6A4 | |
| SCHEMBL6076860 | 0.76 | SLC6A2 (0.44) | P2RX7SLC6A2SLC6A4 | |
| SCHEMBL16268923 | 0.75 | IDO1 (0.45) | IDO1EPHX2P2RX7HDAC3HDAC1 | |
| SCHEMBL937247 | 0.74 | IDO1 (0.59) | IDO1P2RX7HDAC3HDAC1HDAC2 | |
| SCHEMBL8417818 | 0.74 | IDO1 (0.59) | IDO1EPHX2P2RX7HDAC3HDAC1 | |
| SCHEMBL20832037 | 0.74 | IDO1 (0.51) | IDO1EPHX2P2RX7HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| CN-1617849-A | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2005-05-18 | — | — | CN | disclosed |
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | IDO1 510/4885EPHX2 3273/4885P2RX7 4187/4885 |
| US-20030176495-A1 | HIV Integrase inhibitors | MAPT, RIF1, HPRT1 | IDO1 350/4885EPHX2 3611/4885P2RX7 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.